ABSTRACT
Background The coronavirus, which originated in Wuhan, causing the disease called COVID-19, spread more than 200 countries and continents end of the March. There is a lot of data since the virus started. However, these data will be explanatory when accurate analyzes are made and will allow future predictions to be made. In this study, it was aimed to model the outbreak with different time series models and also predict the indicators.
Methods The data was collected from 25 countries which have different process at least 20 days. ARIMA(p,d,q), Simple Exponential Smoothing, Holt’s Two Parameter, Brown’s Double Exponential Smoothing Models were used. The prediction and forecasting values were obtained for the countries. Trends and seasonal effects were also evaluated.
Results China has almost under control according to forecasting. The cumulative death prevalence in Italy and Spain will be the highest, followed by the Netherlands, France, England, China, Denmark, Belgium, Brazil and Sweden respectively as of the first week of April. The highest daily case prevalence was observed in Belgium, America, Canada, Poland, Ireland, Netherlands, France and Israel between 10% and 12%.The lowest rate was observed in China and South Korea. Turkey was one of the leading countries in terms of ranking these criteria. The prevalence of the new case and the recovered were higher in Spain than Italy.
Conclusions More accurate predictions for the future can be obtained using time series models with a wide range of data from different countries by modelling real time and retrospective data.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
https://www.who.int/news-room/detail/08-04-2020-who-timeline---covid-19
